NCT04712097进行中（未招募）3 期
Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a Non-Randomized Single Arm US Extension of Mosunetuzumab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 478
- 试验地点
- 191
- 主要终点
- Progression Free Survival (PFS) according to 2014 Lugano Response Criteria
研究概览
简要总结
This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination with lenalidomide (R + Len) in participants with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least one line of prior systemic therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
- •Histologically documented CD20+ FL (Grades 1-3a)
- •Requiring systemic therapy assessed by investigator based on tumor size and/or Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria
- •Received at least one prior systemic lymphoma therapy, which included prior immunotherapy or chemoimmunotherapy
- •Availability of a representative tumor specimen and the corresponding pathology report at the time of relapse/persistence for confirmation of the diagnosis of FL. Pretreatment sample of at least 1 core-needle, excisional or incisional tumor biopsy is required. Cytological or fine-needle aspiration samples are not acceptable. Fresh pretreatment biopsy is preferred. Patients who are unable to undergo biopsy procedures may be eligible for study enrollment if an archival tumor tissue sample (preferably from the most recent relapse/persistence) as paraffin blocks or at least 15 unstained slides, or in accordance with local regulatory requirements, can be sent to the Sponsor.
- •Adequate hematologic function (unless due to underlying lymphoma, per the investigator)
- •Agreement to comply with all local requirements of the lenalidomide risk minimization plan, which includes the global pregnancy prevention program.
- •For women of childbearing potential: Agreement to remain abstinent (refrain from heterosexual intercourse) or use 2 adequate methods of contraception, including at least 1 method with a failure rate of < 1% per year, for at least 28 days prior to Day 1 of Cycle 1, during the treatment period (including periods of treatment interruption), and for at least 28 days after the last dose of lenalidomide, 3 months after the final dose of tocilizumab (if applicable), mosunetuzumab, and 12 months after final dose of rituximab. Women must refrain from donating eggs during this same period.
- •For men: Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm, as defined: With female partners of childbearing potential or pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 28 days after last dose of lenalidomide, 3 months after the final dose of tocilizumab (if applicable), mosunetuzumab and 12 months after the final dose of rituximab. Men must refrain from donating sperm during this same period.
排除标准
- •* Grade 3b FL
- •* Any history of disease transformation and/or diffuse-large B cell lymphoma (DLBCL)
- •* Documented refractoriness to lenalidomide, defined as no response (partial response or complete response) or relapse within 6 months of therapy
- •* Active or history of CNS lymphoma or leptomeningeal infiltration
- •* Prior standard or investigational anti-cancer therapy as specified: Lenalidomide exposure within 12 months prior to Day 1 of Cycle 1; Chimeric antigen receptor T cell therapy within 30 days prior to Day 1 of Cycle 1; Radioimmunoconjugate within 12 weeks prior to Day 1 of Cycle 1; Monoclonal antibody or antibody-drug conjugate within 4 weeks prior to Cycle 1 Day 1; Treatment with any anti-cancer agent (investigational or otherwise) within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to first dose of study treatment
- •* Clinically significant toxicity (other than alopecia) from prior treatment that has not resolved to Grade \ 20 mg), azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents within 2 weeks prior to Day 1 of Cycle 1
- •* History of solid organ transplantation
- •* History of severe allergic or anaphylactic reaction to humanized, chimeric or murine monoclonal antibodies
- •* Known sensitivity or allergy to murine products
- •* Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary (CHO) cells or any component of the mosunetuzumab, rituximab, tocilizumab, lenalidomide, or thalidomide formulation, including mannitol
- •* History of erythema multiforme, Grade \>/= 3 rash, or blistering following prior treatment with immunomodulatory derivatives
- •* History of interstitial lung disease, drug-induced pneumonitis, and autoimmune pneumonitis
- •* Known active bacterial, viral, fungal, or other infection, or any major episode of infection requiring treatment with IV antibiotics within 4 weeks of Day 1 of Cycle 1
- •* Known or suspected chronic active Epstein-Barr virus (EBV) infection
- •* Known or suspected history of hemophagocytic lymphohistiocytosis
- •* Clinically significant history of liver disease, including viral or other hepatitis, or cirrhosis
- •* Active Hepatitis B infection
- •* Active Hepatitis C infection
- •* Known history of HIV positive status
- •* History of progressive multifocal leukoencephalopathy (PML)
- •* Administration of a live, attenuated vaccine within 4 weeks before first dose of study treatment or anticipation that such a live attenuated vaccine will be required during the study
- •* Other malignancy that could affect compliance with the protocol or interpretation of results
- •* Active autoimmune disease requiring treatment
- •* History of autoimmune disease, including, but not limited to: myocarditis, pneumonitis, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis
- •* Prior allogeneic stem cell transplantation
- •* Contraindication to treatment for thromboembolism prophylaxis
- •* Evidence of any significant, uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including, but not limited to, significant cardiovascular disease (e.g., New York Heart Association Class III or IV cardiac disease, myocardial infarction within the previous 6 months, unstable arrhythmia, or unstable angina) or significant pulmonary disease (such as obstructive pulmonary disease or history of bronchospasm)
- •* Major surgical procedure other than for diagnosis within 28 days prior to Day 1 of Cycle 1 Day 1 or anticipation of a major surgical procedure during the course of the study
- •* Pregnant or lactating or intending to become pregnant during the study
- •* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results
研究组 & 干预措施
R + Len (Arm B)
Experimental
Participants will receive weekly rituximab in Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11. Participants will also receive lenalidomide in Cycles 1-12. (Cycle length = 28 days for Cycles 1-12)
干预措施: Lenalidomide (Drug)
M + Len (US Extension Arm C)
Experimental
Participants will receive mosunetuzumab for 12 cycles, plus lenalidomide from cycles 2-12 (Cycle length = 21 days for Cycle 1; cycle length = 28 days for Cycles 2-12)
干预措施: Mosunetuzumab (Drug)
M + Len (US Extension Arm C)
Experimental
Participants will receive mosunetuzumab for 12 cycles, plus lenalidomide from cycles 2-12 (Cycle length = 21 days for Cycle 1; cycle length = 28 days for Cycles 2-12)
干预措施: Lenalidomide (Drug)
M + Len (Arm A)
Experimental
Participants will receive mosunetuzumab for 12 cycles, plus lenalidomide from cycles 2-12 (Cycle length = 21 days for Cycle 1; cycle length = 28 days for Cycles 2-12)
干预措施: Mosunetuzumab (Drug)
M + Len (Arm A)
Experimental
Participants will receive mosunetuzumab for 12 cycles, plus lenalidomide from cycles 2-12 (Cycle length = 21 days for Cycle 1; cycle length = 28 days for Cycles 2-12)
干预措施: Lenalidomide (Drug)
M + Len (Arm A)
Experimental
Participants will receive mosunetuzumab for 12 cycles, plus lenalidomide from cycles 2-12 (Cycle length = 21 days for Cycle 1; cycle length = 28 days for Cycles 2-12)
干预措施: Tociluzumab (Drug)
R + Len (Arm B)
Experimental
Participants will receive weekly rituximab in Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11. Participants will also receive lenalidomide in Cycles 1-12. (Cycle length = 28 days for Cycles 1-12)
干预措施: Tociluzumab (Drug)
M + Len (US Extension Arm C)
Experimental
Participants will receive mosunetuzumab for 12 cycles, plus lenalidomide from cycles 2-12 (Cycle length = 21 days for Cycle 1; cycle length = 28 days for Cycles 2-12)
干预措施: Tociluzumab (Drug)
R + Len (Arm B)
Experimental
Participants will receive weekly rituximab in Cycle 1, then on Day 1 of Cycles 3, 5, 7, 9, and 11. Participants will also receive lenalidomide in Cycles 1-12. (Cycle length = 28 days for Cycles 1-12)
干预措施: Rituximab (Drug)
结局指标
主要结局
Progression Free Survival (PFS) according to 2014 Lugano Response Criteria
时间窗: From randomization to the first occurrence of disease progression as determined by an independent review committee (IRC) or death from any cause (up to approximately 8.5 years)
次要结局
- Objective Response Rate (ORR)(Up to approximately 8.5 years)
- Overall Survival (OS)(From randomization to death from any cause (up to approximately 8.5 years))
- Duration of Objective Response (DOR)(From the first occurrence of a documented objective response (complete response or partial response) to disease progression or death from any cause, whichever occurs first (up to approximately 8.5 years))
- Duration of Complete Reponse (DOCR)(From the first occurrence of a documented CR to disease progression or death from any cause, whichever occurs first (up to approximately 8.5 years))
- Time to Deterioration in Physical Functioning and Fatigue, as Measured by the European Organisation for Research and Treatment of Cancer Quality of Life-Core 30 Questionnaire (EORTC QLQ-C30)(Up to approximately 8.5 years)
- Time to Deterioration in Lymphoma Symptoms, as Measured by the Functional Assessment of Cancer Therapy-Lymphoma Subscale (FACT-LymS)(Up to approximately 8.5 years)
- PFS as Determined by the Investigator(From randomization to the first occurrence of disease progression or death from any cause (up to approximately 8.5 years))
- Complete Response Rate(Up to approximately 8.5 years)
- Percentage of Participants with Adverse Events (AEs)(Up to approximately 8.5 years)
- Serum Concentration of M + Len(Up to approximately 8.5 years)
- Area Under the Curve (AUC) of M + Len(Up to approximately 8.5 years)
- Percentage of Participants with Anti-Drug Antibodies (ADAs)(Up to approximately 8.5 years)
- Time to New Anti-Lymphoma Treatment (TTNALT)(From randomization to the first documented administration of a new anti-lymphoma treatment (up to approximately 8.5 years))
研究者
研究点 (191)
Loading locations...
相似试验
进行中（未招募）
3 期
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's LymphomaNon-Hodgkin LymphomaNCT05171647Hoffmann-La Roche208
终止
1 期
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin LymphomaNon-Hodgkin Lymphoma, Follicular LymphomaNCT05315713Hoffmann-La Roche8
招募中
2 期
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHLB-Cell LymphomaRelapsed B-cell NHLHodgkin LymphomaNCT05615636M.D. Anderson Cancer Center36
已完成
1 期
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell LymphomaB-cell LymphomaNCT04313608Hoffmann-La Roche23
进行中（未招募）
1 期
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin LymphomaNon-Hodgkin LymphomaNCT05169515Hoffmann-La Roche121